Brief Report: Representations and Willingness of People Living With HIV in Switzerland to Participate in HIV Cure Trials: The Case of Gene-Modified Cell Therapies.

Details

Serval ID
serval:BIB_17341F74FE99
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Brief Report: Representations and Willingness of People Living With HIV in Switzerland to Participate in HIV Cure Trials: The Case of Gene-Modified Cell Therapies.
Journal
Journal of acquired immune deficiency syndromes
Author(s)
Gilles I., Lesage S., Barbieux C., Alessandrini M., Jackson-Perry D., Vittoz L., Peytremann-Bridevaux I., Calmy A.
ISSN
1944-7884 (Electronic)
ISSN-L
1525-4135
Publication state
Published
Issued date
15/08/2021
Peer-reviewed
Oui
Volume
87
Number
5
Pages
1154-1160
Language
english
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Abstract
Recent advances made in cell and gene therapies for cancer suggest that they represent plausible strategies to cure HIV. However, the health risks and constraints associated with these therapies require a deeper understanding of the expectations of such treatments among people living with HIV (PLWH).
We conducted 15 semistructured in-depth interviews among patients from 2 HIV units in Switzerland. After a conversation about their perceptions of research on HIV therapies, participants were provided with a trial description using a gene-modified cell therapy as a potentially curative approach. They were invited to discuss how they might consider participation in the trial. Content analysis was performed to identify core themes.
Participants perceived the trial as burdensome and uncertain. Most were aware that cure was not guaranteed, and 6 of the 15 considered that they would participate. Two main concerns were expressed about potential participation: (1) the impact on the professional life and fear to be stigmatized because of this and (2) the fact that stopping antiretroviral treatment would challenge the balance currently achieved in their lives. The decision to participate would depend on their understanding of the trial, the availability of sufficient information, and the relationship with health care professionals.
Involving PLWH in early stages of research would be crucial to improve their understanding of gene-modified cell therapies. It could also help adapt trials to address key factors, including the anticipation of stigma, which may discourage PLWH from participating in treatment research.
Keywords
Cell- and Tissue-Based Therapy/methods, Genetic Therapy/methods, HIV Infections/therapy, Humans, Qualitative Research, Switzerland, Therapeutic Human Experimentation
Pubmed
Web of science
Open Access
Yes
Create date
15/07/2021 10:26
Last modification date
20/11/2021 6:34
Usage data